Alps Advisors Inc Puma Biotechnology, Inc. Transaction History

Alps Advisors Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 09, 2022	SELL	$2.85 - $6.58 $142,425 - $328,828	-49,974 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$6.63 - $9.39 $21,096 - $29,878	-3,182 Reduced 5.99%	49,974 $350,000
Q2 2021 Aug 11, 2021	SELL	$8.98 - $11.6 $176,672 - $228,218	-19,674 Reduced 27.01%	53,156 $488,000
Q1 2021 May 07, 2021	BUY	$9.38 - $13.63 $10,458 - $15,197	1,115 Added 1.55%	72,830 $708,000
Q4 2020 Feb 03, 2021	BUY	$7.78 - $12.13 $164,298 - $256,161	21,118 Added 41.74%	71,715 $736,000
Q3 2020 Nov 04, 2020	SELL	$9.5 - $11.14 $29,469 - $34,556	-3,102 Reduced 5.78%	50,597 $511,000
Q2 2020 Aug 05, 2020	SELL	$7.01 - $13.24 $120,081 - $226,801	-17,130 Reduced 24.19%	53,699 $560,000
Q1 2020 May 06, 2020	SELL	$6.28 - $14.57 $51,885 - $120,377	-8,262 Reduced 10.45%	70,829 $598,000
Q4 2019 Feb 07, 2020	BUY	$6.5 - $10.73 $10,003 - $16,513	1,539 Added 1.98%	79,091 $692,000
Q3 2019 Nov 04, 2019	SELL	$8.75 - $12.85 $28,420 - $41,736	-3,248 Reduced 4.02%	77,552 $835,000
Q2 2019 Aug 07, 2019	BUY	$12.3 - $35.76 $993,840 - $2.89 Million	80,800 New	80,800 $1.03 Million

102

29.1M

60.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $132M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.